Wide Ranks

IBIO

iBio, Inc.

2.63

Top Statistics
Market Cap 24 M Forward PE -1.60 Revenue Growth 0.00 %
Current Ratio 3.37 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.18 Enterprise / Revenue 99.75 Price To Sales Trailing12 Months 137.50
Profitability
Profit Margins 0.00 % Operating Margins -8935.43 %
Balance Sheet
Total Cash 11 M Total Cash Per Share 1.21 Total Debt 4 M
Total Debt To Equity 24.96 Current Ratio 3.37 Book Value Per Share 2.06
All Measures
Short Ratio 207.00 % Message Board Id finmb_33000 Shares Short Prior Month 307797
Return On Equity -0.9274 City San Diego Uuid f0a2faf7-8166-3ef6-9b69-f7e5c346e13d
Previous Close 2.54 First Trade Date Epoch Utc 1 B Book Value 2.06
Total Debt 4 M Volume 130076 Price To Book 1.28
Last Split Date 1 B Fifty Two Week Low 1.02 Total Cash Per Share 1.21
Total Revenue 175000 Shares Short Previous Month Date 1 B Target Median Price 4.30
Max Age 86400 Recommendation Mean 1.00 Sand P52 Week Change 0.3133
Operating Margins -8935.43 % Target Mean Price 4.30 Net Income To Common -14358000
Ask 2.66 Short Percent Of Float 0.0253 Implied Shares Outstanding 9 M
Last Fiscal Year End 1 B Trailing Peg Ratio None Average Daily Volume10 Day 121610
Average Volume10days 121610 Total Cash 11 M Next Fiscal Year End 1 B
Revenue Per Share 0.0310 Held Percent Insiders 0.0014 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 2.54
Target Low Price 3.60 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.49
Open 2.53 Free Cashflow 10 M State CA
Dividend Yield 0.00 % Return On Assets -0.3143 Time Zone Short Name EST
Trailing Eps -0.2500 Day Low 2.50 Address1 11750 Sorrento Valley Road
Shares Outstanding 9 M Price Hint 4 Target High Price 5.00
Website https://ibioinc.com 52 Week Change -0.1957 Average Volume 130487
Forward Eps -1.64 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 318.20 % Last Split Factor 1:20 Regular Market Day High 2.73
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 24.96
Fifty Two Week High 4.98 Day High 2.73 Shares Short 230876
Regular Market Open 2.53 Industry Key biotechnology Bid 2.61
Earnings Growth 0.00 % Enterprise To Revenue 99.75 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0252 Operating Cashflow -16929000 Currency USD
Time Zone Full Name America/New_York Market Cap 24 M Is_nasdaq_100 False
Zip 92121 Quote Type EQUITY Industry Biotechnology
Long Name iBio, Inc. Regular Market Day Low 2.50 Held Percent Institutions 0.3149
Current Price 2.63 Address2 Suite 200 Enterprise To Ebitda -1.18
Financial Currency USD Current Ratio 3.37 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country United States
Float Shares 7 M Two Hundred Day Average 2.06 Enterprise Value 17 M
Price To Sales Trailing12 Months 137.50 Forward PE -1.60 Regular Market Volume 130076
Ebitda -14753000 Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases.

The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.

Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies.

In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells.

It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases.

iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.